Bromocriptine and uterine neoplasia.

Bromocriptine, dopamine and glaucoma.

The pharmacological control of intraocular pressure (IOP) is as complex as any other physiological system. The influence of the parasympathetic side of the autonomic nervous system, acting through muscarinic cholinergic receptors, has long been known, and cholinergic agonists such as pilocarpine are widely used in treatment of glaucoma. The sympathetic nervous system influences IOP in a remarka...

Bromocriptine and insulin secretion.

The dopaminergic drug bromocriptine inhibited the release of insulin from isolated mouse pancreatic islets. The effect was counteracted by haloperidol or pimozide. It is suggested that insulin release may be inhibited through activation of D-2 dopaminergic receptors in the pancreatic beta-cells.

Bromocriptine in obstetrics and gynaecology.

Bromocriptine, the active ingredient of Parlodel is a specific dopamine receptor agonist available for use in clinical practice. It has been successfully used in the treatment of hyperprolactinemia with associated amenorrhea, galactorrhea and infertility; in the inhibition of postpartum lactation; acromegaly and in Parkinson's disease. Its role in obstetrics and gynaecology is strategic since i...

Bromocriptine reduces cigarette smoking.

AIMS Animal studies have shown that nicotine releases dopamine, a neurotransmitter implicated in drug reinforcement. We hypothesized that bromocriptine would decrease smoking behavior in humans. DESIGN The study was conducted double blind and subjects' order of dose exposure was randomized. PARTICIPANTS The smoking behavior of 20 heavy smokers was recorded for 5 hours after ingesting placeb...

Bromocriptine induced pleuropulmonary fibrosis.